MET and hepatocellular carcinoma: c-MET can trigger various downstream pathways, including the RAS/MAPK and phosphoinositide 3-kinase (PI3K)/AKT pathways, promoting tumor cell proliferation, growth and metastasis in HCC (63, 64).